

SOS AMI Selatogrel

Micha T. Maeder, Karin Fink

Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction

type of project	clinical studies
status	ongoing - recruiting phase
start of project	2022
end of project	2026
study design	prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study
Swissmedic notification number	2021DR3115
responsible person	Prof. Micha Maeder